Proactive - Interviews for investors
Medicus Pharma reports strong Phase 2 dose response in skin cancer study
Medicus Pharma CEO Dr. Raza Bokhari discusses new data from the company’s Phase 2 SKNJCT-003 clinical trial, highlighting a positive dose-response relationship for its Doxorubicin Microneedle Array in the treatment of nodular basal cell carcinoma. The findings suggest the…